Abstract
Background: The rapid evolution of palliative therapeutic choices in the last few years for patients with advanced castration-resistant prostate cancer (CRPC) has resulted in a dilemma currently troubling a few other epithelial malignancies: which systemic agent to choose and at what time? In addition, which specialty specifically directs the delivery of such care-Urology or Medical Oncology-has not been clearly established. Approach: Recognizing the lack of consensus, we propose a framework for Urology and Medical Oncology interactions that is founded on models that have succeeded in the past. Conclusion: This approach aims to focus the care on the patient with CRPC rather than on his physicians and promises to improve patient outcomes in this disease state.
Original language | English (US) |
---|---|
Pages (from-to) | 380-382 |
Number of pages | 3 |
Journal | Urologic Oncology: Seminars and Original Investigations |
Volume | 32 |
Issue number | 4 |
DOIs | |
State | Published - 2014 |
Keywords
- Castration-resistant prostate cancer
- Interactions
- Medical urology
- Urology
ASJC Scopus subject areas
- Oncology
- Urology